Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing
As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue, in 2023, the New Brunswick-based giant has shed its "band-aid and baby powder" image to emerge as a high-octane, pure-play healthcare powerhouse. [...]
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total consideration of up to $5 billion. This strategic maneuver, consisting of $3.15 billion in upfront cash and
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the company’s Phase 3 ATTAIN clinical trial program has revealed that its experimental oral medication, Orforglipron, achieved a staggering
Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase.
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total potential value of $7.8 billion. This massive acquisition is centered on Centessa’s lead asset, cleminorexton (formerly ORX750), a
The S&P 500 (NYSEARCA:SPY) concluded the week ending April 4, 2026, with a resounding 3.4% rally, marking its strongest weekly performance since late 2025. This surge effectively halted a grueling five-week losing streak that had seen the index tumble from its January all-time highs. The primary catalysts
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded (patented) pharmaceutical imports. The announcement, timed to coincide with the first anniversary of "Liberation Day"—the administration's 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects...
Even during a down period for the markets, Pfizer has gone against the grain, climbing to $28.30. Its shares have yielded a 7.1% return over the last six mon...
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for GLP-1 receptor agonists and multi-pathway incretins, once estimated to be a two-horse race, is now the frontline of a
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff on all imported patented pharmaceutical products. The aggressive trade measure is designed to force multinational drugmakers to shift production
